It took a 3-year struggle, but Novartis finally gets a green light on their copycat to Amgen's big blockbuster

Over three years after the first rejection and less than three months after the last one, Novartis has finally earned FDA approval for its biosimilar to Amgen’s $4 billion cancer drug Neulasta. And they’re calling it Ziextenzo.